A chiral D-peptide supramolecular nanoparticle camouflaged with milk extracellular vesicle membranes survived oral delivery, accumulated in tumors, restored p53 signaling for cancer cell killing, and enhanced anti-PD1 immunotherapy across three cancer models.
3 cancer modelsOral DPAICP@ME showed efficacy in melanoma, lung cancer, and patient-derived colon cancer xenograft models
What the researchers found
The chiral peptide supramolecule DPAICP@ME (D-peptide Au(I) infinite covalent polymer camouflaged with milk extracellular vesicle membranes) demonstrated:
- Stability through gastrointestinal absorption and blood circulation after oral administration
- Satisfactory tumor accumulation via oral medication
- Restoration of p53 signaling pathway for cancer therapy
- Efficacy across three cancer models: B16F10 melanoma homograft, LLC Lewis orthotopic lung cancer, and patient-derived orthotopic xenograft (PDOX) colon cancer
- Enhancement of anti-PD1 immunotherapy through further T-cell activation when used in combination
Why it matters
Oral cancer therapy is a long-standing goal in oncology — it would dramatically improve patient quality of life and treatment compliance. This study overcomes two major barriers: peptide degradation in the gut (solved by using protease-resistant D-peptides) and poor absorption (solved by milk vesicle camouflage). The demonstration that an oral peptide nanomedicine can both directly kill cancer cells via p53 and enhance immunotherapy marks a significant advance in peptide-based cancer treatment.
How the study worked
The researchers synthesized a chiral peptide-gold supramolecular nanostructure through an aqueous growth method combining organothiol D-peptides with Au3+. This was then camouflaged with membranes from milk-derived extracellular vesicles. The nanoparticles were characterized for pharmaceutical properties and tested in vivo through oral administration in three mouse cancer models. Combination studies with anti-PD1 immunotherapy evaluated immune activation and T-cell responses.
What this study cannot tell us
All studies were conducted in mouse models — pharmacokinetics, toxicity, and efficacy may differ significantly in humans. The complex multi-component nanostructure (D-peptide + gold + milk vesicle membranes) presents significant manufacturing and regulatory challenges. Long-term safety of gold-containing nanoparticles administered orally is not established. The specific tumor accumulation mechanism and efficiency after oral delivery would need detailed characterization in larger animals before clinical translation.
How to read the evidence
This is a preclinical animal study demonstrating proof of concept across multiple cancer models. While the breadth of testing (3 models + immunotherapy combination) is comprehensive for preclinical work, no human data exists.
When this study was published
Published in 2022, this represents cutting-edge research in oral peptide nanomedicine and chiral peptide nanostructures for cancer therapy.
The bigger picture
This study sits at the intersection of several cutting-edge fields: chiral peptide chemistry, nanomedicine, milk exosome biology, and cancer immunotherapy. The concept of using D-peptides for protease resistance combined with biological membrane camouflage for oral delivery represents a sophisticated multi-engineering approach. If translatable, it could fundamentally change how peptide-based cancer therapies are administered.
Questions still open
- What is the long-term safety profile of orally administered gold-peptide nanoparticles — does gold accumulate in organs?
- Can this platform be manufactured at scale with consistent quality for clinical development?
- Would this oral peptide nanomedicine work in human patients whose tumors have different p53 mutation profiles?
Common questions
Why use D-peptides instead of regular peptides?
How do milk vesicles help the nanoparticles work?
Read the original research
Turing milk into pro-apoptotic oral nanotherapeutic: De novo bionic chiral-peptide supramolecule for cancer targeted and immunological therapy.
Theranostics, 12(5), 2322-2334
Citation
He, Wangxiao; Zhang, Zhang; Yang, Wenguang; Zheng, Xiaoqiang; You, Weiming; Yao, Yu; Yan, Jin; Liu, Wenjia. (2022). Turing milk into pro-apoptotic oral nanotherapeutic: De novo bionic chiral-peptide supramolecule for cancer targeted and immunological therapy.. Theranostics, 12(5), 2322-2334. https://doi.org/10.7150/thno.70568